Fig. 2: Kaplan–Meier estimates of OS and PFS by PD-L1 scoring method and treatment group. | Modern Pathology

Fig. 2: Kaplan–Meier estimates of OS and PFS by PD-L1 scoring method and treatment group.

From: Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer

Fig. 2

OS in patients with (a) TPS ≥ 50% or CPS ≥ 50 or (b) TPS < 50% or CPS < 50. PFS in patients with (c) TPS ≥ 50% or CPS ≥ 50 or (d) TPS < 50% or CPS < 50. CPS combined positive score, OS overall survival, PD-L1 programmed death ligand 1, PFS progression-free survival, SOC standard of care, TPS tumor proportion score.

Back to article page